Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 28, 2015
Pharmacy Choice - News - Front Page Healthcare News - March 28, 2015

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/28/15 - Boston Scientific Gets FDA and CE Mark Approval of the EMBLEM S-ICD System [Manufacturing Close - Up]
Boston Scientific Corp. has received FDA and CE Mark approval of the EMBLEM Subcutaneous Implantable Defibrillator System. A controlled and limited market release has begun in a small number of European centers with a broad European launch scheduled for May 2015 and subsequent U.S. launch planned for the third quarter of 2015.. "We are excited to
3/28/15 - Celator Pharmaceuticals Offers Business Update and Fourth Quarter and Full Year 2014 Financial Results [Health & Beauty Close - Up]
Celator Pharmaceuticals reported business highlights and financial results for the fourth quarter and year ended December 31, 2014. "In 2014, Celator continued to meet important milestones as we look to leverage our CombiPlex platform to introduce a new medical standard for combining cancer therapies," said Scott Jackson, chief executive officer o
3/28/15 - Cidara Appoints Robert Perez and Timothy Franson to Board [Professional Services Close - Up]
"Mr. Perez and Dr. Franson are recognized leaders in the biotechnology and pharmaceutical industries and bring a wealth of complimentary operational experience to our board," said Jeff Stein, Ph.D., chief executive officer of Cidara. He served as executive vice president and chief operating officer for the company from August 2007 to July 2012 and
3/28/15 - Congress Must Bring To An End In Playing Politics with Abortion [National Iraqi News Agency (Iraq)]
The Women's Initiative at the Center for American Progress lately released a concern brief- A Challenge to Congress- that emphasizes quite a few ways that the 114th Congress could improve women's health and economic security. Unfortunately, this Congress is off to a record start in the opposite direction, introducing bills that restrict acces
3/28/15 - Dobson DaVanzo & Associates Addresses 'Addiction Treatment Today And Tomorrow' and Policy Implications [Manufacturing Close - Up]
"Each year substance use disorders have a tangible impact on the societal and economic well-being of the United States," notes a new report from Dobson DaVanzo& Associates, developed for the National Association of Psychiatric Health Systems. The full report, titled "Addiction Treatment Today and Tomorrow: Implications and Policy Recommendations,"
3/28/15 - FDA Approves Biotronik ProMRI Eluna Pacemaker System [Professional Services Close - Up]
Biotronik reported that the Food and Drug Administration has approved its ProMRI Eluna pacemaker system. In a release, Biotronik noted that its ProMRI technology allows patients to undergo full-body magnetic resonance imaging scans with both single-chamber and dual-chamber Eluna pacemakers when implanted with Setrox pacing leads.
3/28/15 - Germany : Bayer receives approval for Gadovist (gadobutrol) injection in Japan [TendersInfo (India)]
Bayer HealthCare received approval in Japan for Gadovist injection for use with magnetic resonance imaging. Gadovist is the first high concentration/high relaxivity gadolinium-based contrast agent to be approved in Japan and is indicated for contrast-enhancement MRI in cranial, spinal, the body and extremeties at a dose of 0.1 mL/kg body weight.
3/28/15 - Hospira's first biosimilar could be its first to gain FDA approval [Chicago Tribune]
March 27 Lake Forest- based Hospira released clinical data Friday for its drug Retacrit, which could become the company's first U.S.-approved biosimilar drug. Retacrit, approved in Europe since 2008, treats anemia as a similar, low-cost version of Amgen's biologic drug Epogen. Hospira submitted its application for Retacrit to the Food and Drug...
3/28/15 - Research and Markets Offers Report: Personal Accident and Health Insurance in Israel, Key Trends and Opportunities to 2018 [Manufacturing Close - Up]
Research and Markets has announced the addition of the " Personal Accident and Health Insurance in Israel, Key Trends and Opportunities to 2018" report to its offerings. The National Health Insurance Law stipulates that every citizen of Israel should be a member of one of the four health maintenance organizations- Clalit, Maccabi, Kupat Holim or Le
3/28/15 - Senate endorses compromise Medicaid expansion plan [The Montana Standard, Butte]
March 28 HELENA The Montana Senate today endorsed a bill to expand Medicaid, under the Affordable Care Act, to cover an estimated 45,000 low-income Montanans. Ed Buttrey, R- Great Falls, the sponsor of the bill, said it would return hundreds of millions of dollars that Montanans have paid to the federal government, to pay for health care for th
3/28/15 - St. Louis-area members of Congress votes for March 23-27 [St. Louis Post-Dispatch]
10- Year Republican Budget The House on March 25 passed, 228-199, a GOP- drafted budget for fiscal 2016-2025 that would cut personal and corporate tax rates, raise military spending, slash domestic spending, repeal the Affordable Care Act, partially privatize Medicare and strive to reach a balanced budget by 2024. A yes vote was to adopt the Repu
3/28/15 - The J.R. Simplot Company's Innate Potato Gets FDA Safety Clearance [Professional Services Close - Up]
The J.R. Simplot Company said it completed the food and feed safety consultation with the Food and Drug Administration for its first generation of Innate potato varieties. In a release, the Company noted that the FDA concluded the Innate potato is as safe and nutritious as conventional potatoes. The FDA statement comes after the recent U. S. Depart
3/28/15 - United States : EMA grants Orphan Drug Designation for REOLYSIN [TendersInfo (India)]
Oncolytics Biotech Inc. declared that the European Medicines Agency has approved Orphan Drug Designation for its lead product candidate, REOLYSIN , for the treatment of ovarian, fallopian tube and primary peritoneal cancers. Oncolytics Biotech Inc is a clinical-stage biotechnology company focused on the development of oncolytic viruses as..
3/27/15 - 21ST CENTURY ONCOLOGY HOLDINGS, INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the "Selected Financial Data" and the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10- K. This section of this Annual Report on Form 10- K contains forward-looking statements that involve substantial risks and uncertainti
3/27/15 - Adamis Pharmaceuticals Receives Complete Response Letter From FDA for Its Epinephrine Pre-Filled Syringe NDA
On May 28, 2014, Adamis submitted an NDA to the FDA pursuant to Section 505 of the Food, Drug& Cosmetic Act, as amended, for approval of the Epinephrine PFS product. The questions raised by the FDA pertain only to Chemistry, Manufacturing and Controls relating to the volume of dose delivered by the syringe, including the ability to deliver volume w
3/27/15 - Bayer receives approval for Gadovist (gadobutrol) injection in Japan
Release date- 26032015- Leverkusen,- Bayer HealthCare received approval in Japan for Gadovist injection for use with magnetic resonance imaging. Gadovist is the first high concentration/high relaxivity gadolinium-based contrast agent to be approved in Japan and is indicated for contrast-enhancement MRI in cranial, spinal, the body and extremeties a
3/27/15 - Boston Scientific Reports First U.S. Commercial Procedures with WATCHMAN Left Atrial Appendage Closure Device [Health & Beauty Close - Up]
Boston Scientific reported that three patients in the United States received the first implants of its WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device received U.S. Food and Drug Administration approval on Friday, March 13. "Boston Scientific is proud to work with physicians in making a meaningful impact on patient lives by brin
3/27/15 - Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk [Health & Beauty Close - Up]
Bristol-Myers Squibb reported the company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases. According to a media release, the agreement supports Bristol- Mye
3/27/15 - Crisis in dental care for Sonoma County, beyond [The Press Democrat, Santa Rosa, Calif.]
Nguyen, who emigrated from Vietnam when he was 15, enrolled in Medi-Cal, the state's low-income medical insurance plan, while studying mechanical engineering at UC Davis. He said he had a difficult time finding specialists, especially dentists who would accept Medi-Cal reimbursement rates, which to this day cover only a fraction of the cost of cari
3/27/15 - DAIICHI SANKYO COMPANY -Announcement Regarding Closure of Merger Between Daiichi Sankyo Subsidiary Ranbaxy and Sun Pharma
Release date- 26032015- Tokyo, Japan- Following its announcement of April 7, 2014, that Sun Pharmaceutical Industries Ltd. was to acquire Ranbaxy Laboratories Limited through a merger entailing an all-stock transaction, Daiichi Sankyo Company, Limited today announced that the aforementioned merger process has been completed. Through this merger...
3/27/15 - Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro? Hair Loss Laser Cap
Earlier this year, the Capillus272Pro? received FDA clearance for the promotion of hair regrowth in adult men and women with androgenic alopecia having Ludwig Savin classifications I-II or Norwood Hamilton classifications of IIa-V and Fitzpatrick Classification of Skin phototypes I-IV. "I am extremely excited that the U.S. Food and Drug Administ
3/27/15 - European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA? (Daclizumab High-Yield Process) for Treatment of MS
CAMBRIDGE, Mass.& NORTH CHICAGO, Ill. Today Biogen and AbbVie announced that the European Medicines Agency has validated the companies Marketing Authorisation Application for ZINBRYTA? for the treatment of relapsing forms of multiple sclerosis in the European Union. We are committed to bringing to market medicines that may provide remar
3/27/15 - FDA Issues Final Order on Classification of Brain Injury Adjunctive Interpretive Electroencephalograph Assessment Aid
WASHINGTON, March 27 The U.S. Department of Health& Human Services published the following rule in the Federal Register from the Food& Drug Administration:. A Rule by the Food and Drug Administration on 03/27/2015. The classification was applicable on November 17, 2014.
3/27/15 - FDA Seeks Comments on Homeopathic Product Regulation
WASHINGTON, March 27 The U.S. Department of Health& Human Services published the following proposed rule in the Federal Register from the Food& Drug Administration:. A Proposed Rule by the Food and Drug Administration on 03/27/2015. Dates: The public hearing will be held on April 20 and 21, 2015, from 9 a.m. to 4 p.m. The meeting may be extended
3/27/15 - Findings from Waikato Hospital Yields New Findings on Arthroplasty (Clinical Outcomes of Total Hip Arthroplasty for Fractured Neck of Femur in...
According to news reporting from Hamilton, New Zealand, by NewsRx journalists, research stated, "To date, there has been little research into the clinical outcomes of total hip arthroplasty for intracapsular neck of femur fracture in the very elderly. 44 patients over 75 years underwent THA for an intracapsular NOF fracture over a two year period.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415